GRAIL公司(GRAL)今日盘前股价大跌47.5%，引发了市场的广泛关注。
消息面上，公司发布的第四季度财报显示净亏损为9920万美元，较上一季度有所增加。同时，公司宣布其关键的多种癌症早期检测试验Galleri未能达到在统计学上显著降低晚期癌症诊断率的主要研究目标，尽管在部分致命癌症中观察到了积极趋势。
这一双重负面消息严重打击了投资者信心。Galleri测试是GRAIL公司的核心产品，其临床试验结果未达主要终点，引发了市场对公司未来增长前景和产品商业化潜力的深度担忧，直接导致了股价在盘前交易时段的大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.